贝达药业：公司团队正尽快递交恩沙替尼新增适应症的NDA申请

Core Viewpoint - The company is actively preparing to submit a New Drug Application (NDA) for a new indication of Ensatinib [2] Group 1 - The company team is accelerating the preparation of submission materials [2] - The NDA application for the new indication of Ensatinib is expected to be submitted soon [2]